11th International Drug Chemistry Conference, Antalya, Türkiye, 9 - 12 Mart 2023, ss.102
Nitrogen-containing heterobicyclic systems are in the framework of many therapeutic agents. Among
the heterobicyclic ring systems, various derivatives fused with pyrazole moiety are reported in the
literature to act by inhibiting proliferation in cancer cells. It was found that the pyrazolopyrazine
skeleton, which is one of the compounds formed by fusing with the pyrazole moiety, has a very high
antiproliferative effect, especially in the lung cancer cell line.1
For example, Compound 1, causes
apoptotic cell death in A549 lung cancer cell line (IC50: 24.2 µM); compound 2 was able to selectively
inhibit the growth of lung cancer cells (H322, IC50: 28.5 µM) in a dose-dependent manner (Fig 1).2,3